Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05849922 | A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa | PHASE2 | COMPLETED | 86 | — | — | Jun 6, 2023 | Jan 9, 2025 | Jan 29, 2026 | 45 | United States, Australia +13 |
The HiSCR50 was used for assessing HS treatment effectiveness in controlling inflammatory manifestations in the population. HiSCR50 was defined as \>=50% reduction from baseline in the total abscess and inflammatory nodule (AN) count, with no increase from baseline in abscess or draining tunnel count. Baseline was defined as the last available value before the first dose of DB study drug. Percentages are rounded off to the tenth decimal place.
| Arm | Type | Description |
|---|---|---|
| SAR442970 | EXPERIMENTAL | Participants received SAR442970 once every two weeks (Q2W) in Period A (Day 1 to Week 16). Participants received SAR442970 Q2W in Period B (Up to Week 28). |
| Placebo | PLACEBO_COMPARATOR | Participants received placebo Q2W in Period A (Day 1 to Week 16). Participants received SAR442970 Q2W in Period B (Up to Week 28). |
| Name | Type | Description |
|---|---|---|
| SAR442970 | DRUG | 1 mL extractable volume of 150 mg/mL SAR442970 filled in 2 mL glass vial |
| Placebo | DRUG | 1 mL extractable volume of placebo filled in 2 mL glass vial |
Inclusion Criteria: * Participants with a history of signs and symptoms consistent with hidradenitis suppurativa (HS) for at least 1 year prior to Baseline. * Participants had to have HS lesions present in at least 2 distinct anatomic areas (eg, left and right axilla; or left axilla and left inguin...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Lutikizumab, Upadacitinib |
| Incyte Corporation | INCY | 6 | PHASE3 | Povorcitinib, povorcitinib, Ruxolitinib, Vehicle |
| Novartis AG Sponsored ADR | NVS | 12 | PHASE3 | secukinumab, Remibrutinib Dose A, Remibrutinib Dose B, CFZ533, LYS006 |
| MoonLake Immunotherapeutics Class A | MLTX | 4 | PHASE3 | Sonelokimab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | Brivekimig, SAR445399 |
| Insmed Incorporated | INSM | 1 | PHASE2 | Brensocatib |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Eltrekibart |
| Pfizer Inc. | PFE | 1 | PHASE2 | Ritlecitinib |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Zura Bio Limited Class A | ZURA | 1 | PHASE2 | Tibulizumab Dose A, Tibulizumab Dose B |
| Sonoma Pharmaceuticals, Inc. | SNOA | 2 | PHASE1 | SBT777101 |
| Evommune, Inc. | EVMN | 1 | EARLY_PHASE1 | EVO101 |